Historical Stock Chart
5 Years : From Aug 2011 to Aug 2016
NovaDel Pharma Inc. (the “Company”) (OTCBB: NVDL) is pleased to announce
that its common stock will begin trading on the Over-the-Counter
Bulletin Board (“OTCBB”) on December 24, 2009. The Company’s new ticker
symbol on OTCBB is NVDL. The Company filed Form 25 on December 14, 2009,
voluntarily withdrawing its listing and registration from NYSE Amex LLC
(“AMEX”). The final day of trading on AMEX was December 23, 2009.
ABOUT NOVADEL PHARMA
NovaDel Pharma Inc. is a specialty pharmaceutical company developing
oral spray formulations for a broad range of marketed drugs. The
Company’s proprietary technology offers, in comparison to conventional
oral dosage forms, the potential for faster absorption of drugs into the
bloodstream leading to quicker onset of therapeutic effects and possibly
reduced first pass liver metabolism, which may result in lower doses.
Oral sprays eliminate the requirement for water or the need to swallow,
potentially improving patient convenience and adherence.
NovaDel’s oral spray technology is focused on addressing unmet medical
needs for a broad array of existing and future pharmaceutical products.
The Company’s most advanced oral spray candidates target angina, nausea,
insomnia, migraine headaches and disorders of the central nervous
system. NovaDel plans to develop these and other products independently
and through collaborative arrangements with pharmaceutical and
biotechnology companies. To find out more about NovaDel Pharma Inc.
(OTCBB: NVDL), visit our website at www.novadel.com.
Except for historical information contained herein, this document may
contain forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve known
and unknown risks and uncertainties that may cause the Company’s actual
results or outcomes to be materially different from those anticipated
and discussed herein including, but not limited to, the ability of third
parties to commercialize the Company’s products, the successful
completion of its pilot pharmacokinetic feasibility studies, the ability
to develop products (independently and through collaborative
arrangements), the Company’s ability to obtain additional required
financing to fund its research programs, the ability to commercialize
and obtain FDA and other regulatory approvals for products under
development, and the acceptance in the marketplace for oral spray
products. The filing of an NDA with the FDA is an important step in the
approval process in the United States. Acceptance for filing by the FDA
does not mean that the NDA has been or will be approved, nor does it
represent an evaluation of the adequacy of the data submitted. Further,
the Company operates in industries where securities may be volatile and
may be influenced by regulatory and other factors beyond the Company’s
control. In addition, our inability to maintain or enter into, and the
risks resulting from our dependence upon, collaboration or contractual
arrangements necessary for the development, manufacture,
commercialization, marketing, sales and distribution of any of our
products could materially impact the Company's actual results. Important
factors that the Company believes might cause such differences are
discussed in the risk factors detailed in the Company’s most recent
Annual Report on Form 10-K and Registration Statements, filed with the
Securities and Exchange Commission. In assessing forward-looking
statements contained herein, if any, the reader is urged to carefully
read all cautionary statements contained in such filings.
For more detailed information regarding NovaDel’s 2009 financial results
and its product pipeline, please review the Company’s SEC filings on
Form 10-Q at the Investor Relations section of www.novadel.com.